Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899806 | 0.85 | CYP2D6 (0.38) | SLC1A3SLC1A2SLC1A1CYP2D6GRM2 | |
| SCHEMBL5899807 | 0.75 | PLG (0.35) | SLC1A3SLC1A2SLC1A1GRM2ARG1 | |
| SCHEMBL5899581 | 0.75 | GRM2 (0.33) | GRM2 | |
| SCHEMBL5899762 | 0.72 | ARG1 (0.34) | SLC1A2GRM2ALOX5ARG1 | |
| SCHEMBL5899650 | 0.71 | SLC6A2 (0.33) | GRM2 | |
| SCHEMBL3546456 | 0.71 | GRM2 (0.35) | CYP2D6GRM2 | |
| SCHEMBL5899790 | 0.70 | ALDH1A1 (0.36) | SLC1A3SLC1A2SLC1A1CYP2D6GRM2 | |
| SCHEMBL5899796 | 0.70 | ALDH1A1 (0.36) | SLC1A3SLC1A2SLC1A1CYP2D6GRM2 | |
| SCHEMBL5899606 | 0.69 | CPB2 (0.31) | — | |
| SCHEMBL5899569 | 0.69 | ALDH1A1 (0.34) | ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1764634-A | Cyclopropyl beta-amino acid derivatives | WARNER LAMBERT CO (US) | 2006-04-26 | — | — | CN | claimed |
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | claimed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004065361-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | claimed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | claimed |
| CN-1764634-A | Cyclopropyl beta-amino acid derivatives | WARNER LAMBERT CO (US) | 2006-04-26 | — | — | CN | disclosed |
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004065361-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | SLC1A3 53/4885SLC1A2 13/4885SLC1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.